From the Focused Ultrasound Surgery Foundation & Fibroid ReliefA new research center for MR-guided focused ultrasound ablation at the University of Virginia is aiming to become a leader in translational and clinical research for emerging interventional procedures.
A new research center for MR-guided focused ultrasound ablation at the University of Virginia is aiming to become a leader in translational and clinical research for emerging interventional procedures.
"The University is proud to be a partner in helping to turn a ‘big idea' into a world-class facility," said Dr. Tim Garson, provost at the University of Virginia, speaking before dedication ceremonies Sept 14. "This will become the leading center for translational research, education, and patient care in the new and rapidly evolving field of MR-guided focused ultrasound."
Focused ultrasound uses MRI guidance to direct multichannel ultrahigh frequency ultrasound to ablate tumors and treat other conditions as an alternative to open surgery or radiation therapy.
The UVA Center will initially offer uterine fibroid therapy, the first application of the focused ultrasound technology to receive FDA approval. In the future, it will also host clinical trials on uterine fibroids and fertility; Parkinson's disease and epilepsy; liver, brain, breast, and prostate tumors; and pain from bony metastasis.
Together, the state of Virginia and the Focused Ultrasound Surgery Foundation covered $7.1 million of the $8 million cost of establishing the institute. Other contributors included GE Healthcare, which manufactures ultrasound and MRI systems, and InSightec, an ultrasound equipment maker.
The center is designed to encourage collaboration between scientists and physicians in biomedical engineering, neurosurgery, surgery, radiology, cardiology, radiation oncology, neurology, urology, and gynecology. Potential applications include:
"The mission of the foundation is to develop new applications and to accelerate the worldwide adoption of focused ultrasound," said Dr. Neal Kassell, UVA professor of neurosurgery. "By creating a center of excellence we can make this happen sooner-and thereby reduce the death, disability, and suffering of untold numbers of patients."
ACR Collaborative Model Achieves 20 Percent Improvement in PI-QUAL Scores for Prostate MRI
May 9th 2024Using a learning network model to discuss challenges and share insights among radiology departments from five different organizations, researchers noted that 87 percent of audited prostate MRI exams had PI-QUAL scores > 4 at the conclusion of the collaborative program.
Breast MRI and Dense Breasts: A Closer Look at Early Findings from a New Prospective Trial
May 2nd 2024Supplemental breast MRI had a cancer detection rate (CDR) of 20/1000 and a positive predictive value (PPV) of 50 percent, according to preliminary findings from a prospective trial involving women with heterogeneously or very dense breasts.